US EditionBoston Scientific appoints Isabel Newton as chief medical officer of its interventional oncology and embolization business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Dr. Isabel Newton Named CMO for Boston Scientific’s Interventional Oncology and Embolization Business
February 3, 2026—Isabel Newton, MD, PhD, has been named Chief Medical Officer of Boston Scientific's Interventional Oncology and Embolization business. The company shared that Dr. Newton is a board-certified diagnostic and interventional radiologist with deep clinical, academic, leadership, and research experience in oncology. Her research has focused on liver cancer, including cancer stem cells, cryoablation, and immuno-oncology. Boston Scienti…
Boston Scientific appoints Isabel Newton as chief medical officer of its interventional oncology and embolization business
Isabel Newton Boston Scientific has announced that Isabel Newton has been named chief medical officer of the company’s interventional oncology (IO) and embolization business. The company have stated that Newton joining Boston Scientific will support deeper engagement across the oncology landscape and strengthen our leadership in a rapidly evolving field. Newton is a board-certified diagnostic and interventional radiologist with deep clinical, ac…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
